- Home
- NBIX vs INCY Comparison
NBIX vs INCY Comparison
Compare NBIX & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | INCY |
|---|---|---|
| Founded | 1992 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 17.0B |
| IPO Year | 1996 | 1993 |
Fundamental Metrics
Financial Performance| Metric | NBIX | INCY |
|---|---|---|
| Price | $155.43 | $102.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $173.79 | $90.71 |
| AVG Volume (30 Days) | 969.9K | ★ 2.0M |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.44 | ★ 3878.02 |
| EPS | 4.19 | ★ 5.90 |
| Revenue | $2,682,700,000.00 | ★ $4,813,105,000.00 |
| Revenue This Year | $23.76 | $19.59 |
| Revenue Next Year | $18.01 | $10.88 |
| P/E Ratio | $37.10 | ★ $17.37 |
| Revenue Growth | ★ 19.61 | 18.09 |
| 52 Week Low | $84.23 | $53.56 |
| 52 Week High | $157.67 | $109.28 |
Technical Indicators
Market Signals| Indicator | NBIX | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 54.83 |
| Support Level | $150.26 | $100.55 |
| Resistance Level | $154.35 | $107.61 |
| Average True Range (ATR) | 4.16 | 2.94 |
| MACD | 1.07 | -0.98 |
| Stochastic Oscillator | 93.25 | 45.19 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.